| Quarter | Filling ID |
|---|---|
| Q4 25 | 0002002654-26-000001 |
| Q3 25 | 0002002654-25-000006 |
| Q2 25 | 0002002654-25-000004 |
| Q1 25 | 0002002654-25-000003 |
| Q4 24 | 0002002654-25-000001 |
| Q3 24 | 0002002654-24-000005 |
| Q2 24 | 0002002654-24-000004 |
| Q1 24 | 0002002654-24-000002 |
| Q4 23 | 0002002654-24-000001 |
| Q3 23 | 0002002654-23-000008 |
| Q2 23 | 0002002654-23-000007 |
| Q1 23 | 0002002654-23-000006 |
| Q4 22 | 0002002654-23-000005 |
| Q3 22 | 0002002654-23-000004 |
| Q2 22 | 0002002654-23-000003 |
| Q1 22 | 0002002654-23-000002 |
| Q4 21 | 0002002654-23-000001 |
| Name | Title | CUSIP | Ticker | Value | Shares | Share Price | Investment | % of Portfolio |
|---|---|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP | Common | 91307C102 | $1,024,482,515 | 2,858,888 | SOLE | |||
| ASCENDIS PHARMA | Sponsored ADR | 04351P101 | $744,890,867 | 4,988,888 | SOLE | |||
| ARGENX SE | Sponsored ADR | 04016X101 | $671,348,191 | 1,238,467 | SOLE | |||
| KRYSTAL BIOTECH INC | Common | 501147102 | $477,323,071 | 2,622,222 | SOLE | |||
| MADRIGAL PHARMACEUTICALS INC | Common | 558868105 | $430,594,380 | 2,029,000 | SOLE | |||
| APELLIS PHARMACEUTICALS INC. | Common | 03753U106 | $320,444,441 | 11,111,111 | SOLE | |||
| SAREPTA THERAPEUTICS INC | Common | 803607100 | $319,163,264 | 2,555,555 | SOLE | |||
| AVIDITY BIOSCIENCES INC | Common | 05370A108 | $315,768,750 | 6,875,000 | SOLE | |||
| AMICUS THERAPEUTICS INC. | Common | 03152W109 | $247,509,000 | 23,175,000 | SOLE | |||
| INTRA-CELLULAR THERAPIES INC | Common | 46116X101 | $223,168,500 | 3,050,000 | SOLE | |||
| XENON PHARMACEUTICALS INC | Common | 98420N105 | $223,096,640 | 5,666,666 | SOLE | |||
| KYMERA THERAPEUTICS INC | Common | 501575104 | $212,985,000 | 4,500,000 | SOLE | |||
| VERA THERAPEUTICS INC | Common | 92337R101 | $190,483,878 | 4,309,590 | SOLE | |||
| ARROWHEAD PHARMACEUTICALS INC. | Common | 04280A100 | $172,177,761 | 8,888,888 | SOLE | |||
| BIOMARIN PHARMACEUTICAL INC | Common | 09061G101 | $143,252,074 | 2,038,015 | SOLE | |||
| MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | $139,668,442 | 2,770,100 | SOLE | |||
| VAXCYTE INC | Common | 92243G108 | $134,267,250 | 1,175,000 | SOLE | |||
| SOLENO THERAPEUTICS INC | Common | 834203309 | $110,118,690 | 2,181,000 | SOLE | |||
| BIOCRYST PHARMACEUTICALS INC | Common | 09058V103 | $90,174,000 | 11,865,000 | SOLE | |||
| SYNDAX PHARMACEUTICALS INC | Common | 87164F105 | $74,852,412 | 3,888,437 | SOLE | |||
| OCULAR THERAPEUTIX INC | Common | 67576A100 | $70,122,000 | 8,060,000 | SOLE | |||
| KURA ONCOLOGY INC | Common | 50127T109 | $69,201,008 | 3,541,505 | SOLE | |||
| MERUS N V | Common | N5749R100 | $67,695,800 | 1,355,000 | SOLE | |||
| TOURMALINE BIO INC | Common | 89157D105 | $57,133,328 | 2,222,222 | SOLE | |||
| MANNKIND CORP | Common | 56400P706 | $55,037,500 | 8,750,000 | SOLE | |||
| ULTRAGENYX PHARMACEUTICAL INC | Common | 90400D108 | $46,106,500 | 830,000 | SOLE | |||
| AUTOLUS THERAPEUTICS PLC | Sponsored ADR | 05280R100 | $44,814,811 | 12,345,678 | SOLE | |||
| IOVANCE BIOTHERAPEUTICS INC | Common | 462260100 | $39,813,600 | 4,240,000 | SOLE | |||
| TAYSHA GENE THERAPIES INC | Common | 877619106 | $37,486,500 | 18,650,000 | SOLE | |||
| MONTE ROSA THERAPEUTICS INC | Common | 61225M102 | $30,688,251 | 5,790,236 | SOLE | |||
| CG ONCOLOGY INC | Common | 156944100 | $26,411,000 | 700,000 | SOLE | |||
| DYNE THERAPEUTICS INC. | Common | 26818M108 | $23,348,000 | 650,000 | SOLE | |||
| SPYRE THERAPEUTICS INC | Common | 00773J202 | $17,604,826 | 598,600 | SOLE | |||
| AADI BIOSCIENCES INC | Common | 00032Q104 | $5,869,768 | 2,849,402 | SOLE | |||
| NEUROGENE INC | Common | 64135M105 | $924,337 | 22,029 | SOLE | |||
| INSMED INC | Common | 457669957 | $125,000 | 50,000 | SOLE |